VolitionRx Announces Launch Details for DETECSEPS Sepsis Detection Program in France
VolitionRx Limited, a multinational epigenetics company listed on NYSE AMERICAN (VNRX), has announced further details regarding the official launch of the DETECSEPS program in France. The initiative is part of a government-funded consortium aimed at improving early detection and management of sepsis through innovative diagnostic tools. The DETECSEPS project combines clinical evaluation with Volition's Nu.Q® NETs H3.1 biomarker, which measures immune response linked to sepsis, alongside IDS France’s i10 device for rapid testing. The program will evaluate this approach in 1,000 patients across emergency departments and is backed by €6.3 million (~$7.3 million) in funding. If successful, the initiative could significantly improve patient outcomes through faster diagnosis and more efficient care pathways while reducing hospitalizations and healthcare costs.
Topics: biotechnology medical research partnerships sepsis detection